Copyright
©The Author(s) 2016.
World J Hepatol. Jul 28, 2016; 8(21): 891-901
Published online Jul 28, 2016. doi: 10.4254/wjh.v8.i21.891
Published online Jul 28, 2016. doi: 10.4254/wjh.v8.i21.891
Baseline sCr | A value of sCr obtained in the previous 3 mo, when available, can be used as baseline sCr. In patients with more than one value within the previous 3 mo, the value closest to the admission time to the hospital should be used. In patients without a previous sCr value, the sCr on admission should be used as baseline |
Definition of AKI | Increase in sCr ≥ 0.3 mg/dL (≥ 26.5 mmol/L) within 48 h; or a percentage increase sCr ≥ 50% from baseline which is known, or presumed, to have occurred within the prior 7 d |
Staging of AKI | Stage 1: Increase in sCr ≥ 0.3 mg/dL (26.5 mmol/L) or an increase in sCr ≥ 1.5-fold to twofold from baseline Stage 2: Increase in sCr > two to threefold from baseline Stage 3: Increase of sCr > threefold from baseline or sCr ≥ 4.0 mg/dL (353.6 mmol/L) with an acute increase ≥ 0.3 mg/dL (26.5 mmol/L) or initiation of renal replacement therapy |
Progression of AKI | Progression: Progression of AKI to a higher stage and/or need for RRT |
Regression: Regression of AKI to a lower stage | |
Response to treatment | No response: No regression of AKI |
Partial response: Regression of AKI stage with a reduction of sCr to ≥ 0.3 mg/dL (26.5 mmol/L) above the baseline value | |
Full response: Return of sCr to a value within 0.3 mg/dL (26.5 mmol/L) of the baseline value |
- Citation: Peres LAB, Bredt LC, Cipriani RFF. Acute renal injury after partial hepatectomy. World J Hepatol 2016; 8(21): 891-901
- URL: https://www.wjgnet.com/1948-5182/full/v8/i21/891.htm
- DOI: https://dx.doi.org/10.4254/wjh.v8.i21.891